Stock listing
NASDAQ:TCGX TCGX Acquisition Corp. Stock
Follow TCGX Acquisition Corp. into a list and get an email when it puts out news.
Share price · NASDAQ:TCGX
$10.02 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $10.00 – $10.03 USDNov 20, 2026
- Volume
- 123,234 sharesNov 20, 2026
- Market cap
- $91.66M USDAt the close on Nov 20, 2026 · price × 9.15M shares outstanding
- Traded on an average day
- $1.19M USDMedian day 22,800 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TCGX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.02 | 0.00 | 0.0% | $10.00 | $10.03 | $10.00 | 123,234 | |
| $10.02 | -0.01 | -0.1% | $10.02 | $10.04 | $10.02 | 13,935 | |
| $10.03 | +0.03 | +0.3% | $10.02 | $10.03 | $10.02 | 49,520 | |
| $10.00 | -0.01 | -0.1% | $10.02 | $10.02 | $10.00 | 18,739 | |
| $10.01 | -0.015 | -0.1% | $10.01 | $10.02 | $10.01 | 1,150 | |
| $10.03 | -0.015 | -0.1% | $10.06 | $10.06 | $10.01 | 9,491 | |
| $10.04 | 0.00 | 0.0% | $10.04 | $10.04 | $10.04 | 10,529 | |
| $10.04 | -0.01 | -0.1% | $10.05 | $10.06 | $10.01 | 8,956 | |
| $10.05 | +0.01 | +0.1% | $10.05 | $10.05 | $10.01 | 9,608 | |
| $10.04 | +0.01 | +0.1% | $10.03 | $10.04 | $10.03 | 1,426 | |
| $10.03 | -0.01 | -0.1% | $10.03 | $10.03 | $10.01 | 122,800 | |
| $10.04 | +0.01 | +0.1% | $10.05 | $10.05 | $10.02 | 54,114 | |
| $10.03 | 0.00 | 0.0% | $10.03 | $10.05 | $10.03 | 13,961 | |
| $10.03 | -0.005 | 0.0% | $10.03 | $10.08 | $10.02 | 18,839 | |
| $10.04 | -0.025 | -0.2% | $10.06 | $10.08 | $10.02 | 47,669 | |
| $10.06 | -0.025 | -0.2% | $10.10 | $10.10 | $10.05 | 132,292 | |
| $10.09 | -0.015 | -0.1% | $10.12 | $10.12 | $10.07 | 35,398 | |
| $10.10 | -0.04 | -0.4% | $10.15 | $10.16 | $10.05 | 423,428 | |
| $10.14 | +0.04 | +0.4% | $10.11 | $10.14 | $10.10 | 88,249 | |
| $10.10 | +0.07 | +0.7% | $10.02 | $10.15 | $10.02 | 178,600 | |
| $10.03 | +0.03 | +0.3% | $10.02 | $10.06 | $10.00 | 296,700 | |
| $10.00 | -0.01 | -0.1% | $10.02 | $10.08 | $9.99 | 643,100 | |
| $10.01 | -0.01 | -0.1% | $10.03 | $10.11 | $10.00 | 1,084,500 | |
| $10.02 | -2.28 | -18.5% | $12.10 | $12.27 | $9.90 | 1,796,200 | |
| $12.30 | -0.06 | -0.5% | $12.80 | $12.80 | $12.30 | 500 | |
| $12.36 | -0.52 | -4.0% | $12.36 | $12.36 | $12.36 | 200 | |
| $12.88 | +0.52 | +4.2% | $12.47 | $13.30 | $12.43 | 18,700 | |
| $12.36 | +0.04 | +0.3% | $12.21 | $16.99 | $12.09 | 24,500 | |
| $12.32 | -0.19 | -1.5% | $12.32 | $12.32 | $12.32 | 1,100 | |
| $12.51 | +0.48 | +4.0% | $12.24 | $12.59 | $12.24 | 900 | |
| $12.03 | -0.56 | -4.4% | $12.35 | $12.35 | $12.03 | 1,100 | |
| $12.59 | -0.16 | -1.3% | $12.58 | $12.59 | $12.58 | 300 | |
| $12.75 | 0.00 | 0.0% | $12.75 | $12.75 | $12.75 | 0 | |
| $12.75 | 0.00 | 0.0% | $12.75 | $12.75 | $12.75 | 0 | |
| $12.75 | +0.50 | +4.1% | $12.75 | $12.75 | $12.75 | 2,000 | |
| $12.25 | -0.26 | -2.1% | $12.91 | $12.91 | $11.77 | 28,900 | |
| $12.51 | -0.86 | -6.4% | $13.47 | $13.50 | $12.50 | 7,400 | |
| $13.37 | -0.28 | -2.1% | $13.74 | $13.88 | $13.37 | 7,200 | |
| $13.65 | -0.45 | -3.2% | $13.80 | $13.92 | $13.45 | 9,000 | |
| $14.10 | -0.28 | -1.9% | $14.45 | $14.46 | $14.10 | 5,400 | |
| $14.38 | -0.35 | -2.4% | $14.47 | $14.85 | $13.71 | 14,700 | |
| $14.73 | +0.18 | +1.2% | $14.00 | $15.40 | $14.00 | 17,800 | |
| $14.55 | +0.24 | +1.7% | $14.70 | $15.28 | $13.90 | 36,600 | |
| $14.31 | -0.34 | -2.3% | $14.40 | $15.25 | $13.81 | 22,800 | |
| $14.65 | -0.38 | -2.5% | $14.85 | $15.00 | $14.65 | 5,900 | |
| $15.03 | +1.18 | +8.5% | $14.00 | $16.00 | $13.83 | 54,600 | |
| $13.85 | +0.55 | +4.1% | $13.50 | $14.21 | $13.13 | 20,200 | |
| $13.30 | +0.29 | +2.2% | $13.25 | $13.30 | $13.19 | 5,500 | |
| $13.01 | -0.43 | -3.2% | $14.22 | $14.22 | $13.00 | 23,900 | |
| $13.44 | -0.27 | -2.0% | $13.65 | $14.00 | $12.48 | 28,800 | |
| $13.71 | -0.04 | -0.3% | $13.75 | $13.94 | $13.48 | 42,500 | |
| $13.75 | -0.26 | -1.9% | $13.83 | $14.10 | $13.53 | 55,100 | |
| $14.01 | -0.04 | -0.3% | $14.05 | $14.26 | $13.65 | 12,200 | |
| $14.05 | -0.14 | -1.0% | $14.01 | $14.35 | $13.63 | 17,100 | |
| $14.19 | -0.03 | -0.2% | $14.04 | $14.70 | $14.02 | 41,600 | |
| $14.22 | +0.27 | +1.9% | $14.15 | $14.51 | $13.75 | 168,800 | |
| $13.95 | -0.15 | -1.1% | $13.97 | $14.10 | $13.57 | 53,500 | |
| $14.10 | +0.43 | +3.1% | $13.83 | $14.40 | $13.29 | 38,500 | |
| $13.67 | -0.11 | -0.8% | $13.69 | $14.90 | $13.26 | 325,500 | |
| $13.78 | -0.13 | -0.9% | $13.83 | $14.00 | $13.26 | 73,300 | |
| $13.91 | +0.02 | +0.1% | $13.88 | $14.08 | $13.58 | 99,200 | |
| $13.89 | -0.11 | -0.8% | $14.01 | $14.75 | $13.21 | 26,800 | |
| $14.00 | +0.10 | +0.7% | $13.24 | $14.04 | $13.24 | 20,700 | |
| $13.90 | -0.20 | -1.4% | $13.00 | $15.05 | $13.00 | 137,000 | |
| $14.10 | -0.79 | -5.3% | $15.24 | $16.25 | $13.22 | 395,500 |
- Ticker
- NASDAQ:TCGX
- Asset type
- Stock
- Sector
- Financials
- Industry
- Shell companies & SPACs
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors
Latest deck · Oct 19, 2026
SPAC Merger (October 2026)
SPAC merger · 31 slides
Latest news
TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors
Nov 9, 2026
Closed $10.05 (+0.1%) on Nov 9, 2026
TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Nov 2, 2026
Closed $10.03 (0.0%) on Nov 2, 2026
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine
Oct 19, 2026
Closed $10.02 (-18.5%) on Oct 19, 2026
TCGX Acquisition Corp. II Announces Pricing of $100,000,000 Initial Public Offering
Oct 15, 2026
Closed $12.30 (-0.5%) on Oct 16, 2026
TCGX Acquisition Corp. Announces Completion of its Initial Public Offering
Aug 6, 2026
Closed $12.70 (+8.0%) on Aug 7, 2026
TCGX Acquisition Corp. on 6ix
- Sector
- Financials
- Industry
- Shell companies & SPACs
- News releases
- 5 in the last 12 months · 5 in all · newest Nov 9, 2026 · oldest 2026
- Decks
- 1 deck · latest Oct 19, 2026
Valuation
balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $91.66M USD
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Shell companies & SPACs: the 10 companies nearest in size, of 284 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TCGX Acquisition Corp. · NASDAQ:TCGX | US$91.66M | US$91.66M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Future Vision II Acquisition Corporation · NASDAQ:FVN | US$101.5M | US$100.7M | 58.6× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| Charlton Aria Acquisition Corporation · NASDAQ:CHAR | US$97.20M | US$97.16M | 46.9× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| Tavia Acquisition Corp. · NASDAQ:TAVI | US$94.80M | US$94.69M | 73.1× | n/a | n/a | n/a | n/a | n/a | 0.02 |
| Research Alliance Corporation IV · NASDAQ:RACD | US$93.90M | US$93.90M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Miluna Acquisition Corp · NASDAQ:MMTX | US$90.80M | US$90.70M | n/a | n/a | n/a | n/a | n/a | n/a | 0.01 |
| ChampionsGate Acquisition Corporation · NASDAQ:CHPG | US$90.74M | US$90.72M | 39.6× | n/a | n/a | n/a | n/a | n/a | 0.00 |
| Origin Investment Corp I · NASDAQ:ORIQ | US$90.13M | US$89.79M | 56.9× | n/a | n/a | 288× | n/a | 0.0× | 0.00 |
| Archimedes Tech SPAC Partners II Co. · NASDAQ:ATII | US$89.95M | US$89.54M | n/a | n/a | n/a | n/a | n/a | n/a | 0.51 |
| Peace Acquisition Corp · NASDAQ:PECE | US$84.97M | US$84.70M | n/a | n/a | n/a | 505× | n/a | 0.0× | n/a |
| JATT II Acquisition Corp · NASDAQ:JATT | US$81.82M | US$80.82M | n/a | n/a | n/a | n/a | n/a | n/a | 0.13 |
| Median of the others | US$90.77M | US$90.71M | 56.9× | 396× | 0.0× | 0.02 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| SPAC Merger (October 2026) | SPAC merger | 31 slides | Oct 19, 2026 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock (PIPE) Announced: US$160M · US$10 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Cantor, LifeSci Capital Buyers: TCGX; Viking Global Investors; ADAR1 Capital Management; BVF Partners; Samsara BioCapital; Vianti Capital Use of proceeds: Complete Phase 3 trials of elismetrep and submit an NDA, run a migraine prevention trial, and prepare for a potential U.S. launch | Oct 19, 2026 |
| Public offering of class A ordinary shares Closed: US$10 a share · Jefferies Dealers: Jefferies (lead) | Aug 6, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
A blank check company (SPAC). Priced at US$10.00 a share on Aug 4, 2026.
- Price
- US$10.00 a share
- Shares offered
- 7,500,000 Class A ordinary shares
- Offering size
- US$75 million
- Underwriters' option
- Up to 1,125,000 more shares
- Listing
- TCGX on the Nasdaq Capital Market
- Underwriter
- Jefferies
- Shares delivered
- On or about Aug 6, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 23, 2026 |
| Filed publicly | Jul 20, 2026 |
| Amended once | Jul 31, 2026 |
| Shares registered with an exchange | Aug 4, 2026 |
| Declared effective by the SEC | Aug 4, 2026 |
| Final prospectus, with the price | Aug 6, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 6, 2026 |
| EFFECT · Notice that a registration is effective | Aug 4, 2026 |
| CERT · Exchange's certificate of listing | Aug 4, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 4, 2026 |
| S-1/A · Registration statement, amended | Jul 31, 2026 |
| S-1 · Registration statement | Jul 20, 2026 |
| DRS · Draft registration statement | Jun 23, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 6, 2026
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 425 | Nov 9, 2026 | Other filings | SEC |
| 425 | Nov 2, 2026 | Other filings | SEC |
| 425 | Oct 19, 2026 | Other filings | SEC |
| 425 | Oct 19, 2026 | Other filings | SEC |
| 425 | Oct 19, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
All 29 filings
Cap table
Built by 6ix from TCGX Acquisition Corp.’s releases · as of Oct 19, 2026
- Common shares
- 9,147,500
- Fully diluted
- 9,147,500
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 9,147,500 | Aug 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 6, 2026 | 9,147,500 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lin Wei Other companies: Revolution Medicines, Inc. (Chief Medical Officer · Since at least Mar 21, 2024); 2Seventy Bio Inc (Director · Mar 7, 2023 – May 13, 2025 · Past); Erasca, Inc. (Chief Medical Officer · Jul 15, 2021 – Feb 1, 2023 · Past) | Director · Since at least Aug 4, 2026 |
| Chen-Ming Yu Other companies: TCGX Acquisition Corp. II (Chief Executive Officer, Director · Since at least Oct 19, 2026); Sagent Pharmaceuticals Inc (Interim COO · Apr 19, 2011 – Sep 7, 2012 · Past) | Chief Executive Officer · Since at least Aug 4, 2026 |
| Ying Huang Other companies: ADARx Pharmaceuticals, Inc. (Board Member · Since at least Sep 24, 2026); Legend Biotech Corp. (Chief Executive Officer, Director · Since at least Mar 18, 2026) | Director · Since at least Aug 4, 2026 |
| Craig David Skaling | Chief Financial Officer · Since at least Aug 4, 2026 |
| Daniel Lynch | Chairman of the TriGemX Bio Board of Directors · Since Nov 9, 2026 |
Log in to ask 6ix AI your own questions about TCGX Acquisition Corp.